

CITATION REPORT

List of articles citing

Longitudinal plasma amyloid beta in Alzheimer's disease clinical trials

DOI: 10.1016/j.jalz.2014.07.156

Alzheimer's and Dementia, 2015, 11, 1069-79.

Source: <https://exaly.com/paper-pdf/62324482/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
17	The down syndrome biomarker initiative (DSBI) pilot: proof of concept for deep phenotyping of Alzheimer's disease biomarkers in down syndrome. <i>Frontiers in Behavioral Neuroscience</i> , 2015 , 9, 239	3.5	60
16	Oral glucose tolerance testing to modulate plasma amyloid levels: A novel biomarker. <i>Alzheimers and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2015 , 1, 311-315	5.2	0
15	Peripheral Fluid-Based Biomarkers of Alzheimer's Disease. 2016 , 183-218		0
14	The clinical significance of plasma clusterin and A β in the longitudinal follow-up of patients with Alzheimer's disease. <i>Alzheimers Research and Therapy</i> , 2017 , 9, 91	9	18
13	Effects of Meditation and Music-Listening on Blood Biomarkers of Cellular Aging and Alzheimer's Disease in Adults with Subjective Cognitive Decline: An Exploratory Randomized Clinical Trial. <i>Journal of Alzheimers Disease</i> , 2018 , 66, 947-970	4.3	21
12	Associations between Plasma Biomarkers and Cognition in Patients with Alzheimer's Disease and Amnesic Mild Cognitive Impairment: A Cross-Sectional and Longitudinal Study. <i>Journal of Clinical Medicine</i> , 2019 , 8,	5.1	13
11	Nanowired delivery of cerebrolysin with neprilysin and p-Tau antibodies induces superior neuroprotection in Alzheimer's disease. <i>Progress in Brain Research</i> , 2019 , 245, 145-200	2.9	17
10	Changes in Plasma Amyloid and Tau in a Longitudinal Study of Normal Aging, Mild Cognitive Impairment, and Alzheimer's Disease. <i>Dementia and Geriatric Cognitive Disorders</i> , 2019 , 48, 180-195	2.6	11
9	Amyloid- β as a Blood Biomarker for Alzheimer's Disease: A Review of Recent Literature. <i>Journal of Alzheimers Disease</i> , 2020 , 73, 819-832	4.3	14
8	Dynamic Blood Concentrations of A β and A β in Alzheimer's Disease. <i>Frontiers in Cell and Developmental Biology</i> , 2020 , 8, 768	5.7	3
7	Alterations of aqueous humor A β levels in A β -infused and transgenic mouse models of Alzheimer disease. <i>PLoS ONE</i> , 2020 , 15, e0227618	3.7	10
6	Statins in Neuro-ophthalmology. <i>Neuro-Ophthalmology</i> , 2021 , 45, 219-237	0.9	
5	An elaborative NMR based plasma metabolomics study revealed metabolic derangements in patients with mild cognitive impairment: a study on north Indian population. <i>Metabolic Brain Disease</i> , 2021 , 36, 957-968	3.9	5
4	Can blood amyloid levels be used as a biomarker for Alzheimer's disease?. <i>Brain Science Advances</i> , 2021 , 7, 17-25	2	1
3	A Workshop on Cognitive Aging and Impairment in the 9/11-Exposed Population. <i>International Journal of Environmental Research and Public Health</i> , 2021 , 18,	4.6	5
2	The genetic and environmental etiology of blood-based biomarkers related to risk of Alzheimer's Disease in a population-based sample of early old-age men.		
1	Effects of Simvastatin on Plasma Amyloid- β Transport in Patients with Hyperlipidemia: A 12-Week Randomized, Double-Blind, Placebo-Controlled Trial. 2022 , 1-14		0

